Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report
Yıl: 2023 Cilt: 45 Sayı: 1 Sayfa Aralığı: 101 - 103 Metin Dili: İngilizce DOI: 10.14744/etd.2022.21043 İndeks Tarihi: 28-05-2023
Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report
Öz: Background: Palbociclib is a potent cyclin-dependent kinase (CDK) 4/6 inhibitor that impairs cell cycle progression. It has recently been approved for patients with hormone receptor positive metastatic breast cancer. Case Report: We report the response achieved palbociclib plus fulvestrant therapy in a 68-year-old female breast cancer patient with bone marrow metastasis. She treated with paclitaxel weekly chemotherapy, but no response was obtained. Then, with dose reduction palbociclib 75 mg/day, plus fulvestrant treatment was administered. After 6 cycles, thrombocyto- penia resolved and the palbociclib dose was increased to 125 mg/day. Cytopenia completely resolved after the eight cycle treatments. She is still going on treatment without progression and side effects. Conclusion: The efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow metastases have not been clarified. However, palbociclib treatment can be given with close follow-up and dose reduction in breast cancer patients with bone marrow metastasis.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
- 1. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 2016; 13(7): 417–30.
- 2. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treat- ment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17(4): 425–39. Erratum in: Lan- cet Oncol 2016; 17(4): e136. Erratum in: Lancet Oncol 2016; 17(7): e270.
- 3. Kopp HG, Krauss K, Fehm T, Staebler A, Zahm J, Vogel W, et al. Symptomatic bone marrow involvement in breast cancer--clinical pre- sentation, treatment, and prognosis: a single institution review of 22 cases. Anticancer Res 2011; 31(11): 4025–30.
- 4. Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, et al. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open 2018; 3(5): e000368.
- 5. Yamaguchi T, Masumoto M, Sakurai U, Nakane M. Disseminated car- cinomatosis of the bone marrow from occult breast cancer responding to a sequence of endocrine therapy. Case Rep Oncol 2020; 13(1): 193–9.
| APA | MUTLU E, Ozkan M, Fırat S, Coşar R (2023). Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. , 101 - 103. 10.14744/etd.2022.21043 |
| Chicago | MUTLU EMEL,Ozkan Metin,Fırat Sedat Tarık,Coşar Ramazan Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. (2023): 101 - 103. 10.14744/etd.2022.21043 |
| MLA | MUTLU EMEL,Ozkan Metin,Fırat Sedat Tarık,Coşar Ramazan Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. , 2023, ss.101 - 103. 10.14744/etd.2022.21043 |
| AMA | MUTLU E,Ozkan M,Fırat S,Coşar R Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. . 2023; 101 - 103. 10.14744/etd.2022.21043 |
| Vancouver | MUTLU E,Ozkan M,Fırat S,Coşar R Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. . 2023; 101 - 103. 10.14744/etd.2022.21043 |
| IEEE | MUTLU E,Ozkan M,Fırat S,Coşar R "Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report." , ss.101 - 103, 2023. 10.14744/etd.2022.21043 |
| ISNAD | MUTLU, EMEL vd. "Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report". (2023), 101-103. https://doi.org/10.14744/etd.2022.21043 |
| APA | MUTLU E, Ozkan M, Fırat S, Coşar R (2023). Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. Erciyes Medical Journal, 45(1), 101 - 103. 10.14744/etd.2022.21043 |
| Chicago | MUTLU EMEL,Ozkan Metin,Fırat Sedat Tarık,Coşar Ramazan Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. Erciyes Medical Journal 45, no.1 (2023): 101 - 103. 10.14744/etd.2022.21043 |
| MLA | MUTLU EMEL,Ozkan Metin,Fırat Sedat Tarık,Coşar Ramazan Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. Erciyes Medical Journal, vol.45, no.1, 2023, ss.101 - 103. 10.14744/etd.2022.21043 |
| AMA | MUTLU E,Ozkan M,Fırat S,Coşar R Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. Erciyes Medical Journal. 2023; 45(1): 101 - 103. 10.14744/etd.2022.21043 |
| Vancouver | MUTLU E,Ozkan M,Fırat S,Coşar R Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. Erciyes Medical Journal. 2023; 45(1): 101 - 103. 10.14744/etd.2022.21043 |
| IEEE | MUTLU E,Ozkan M,Fırat S,Coşar R "Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report." Erciyes Medical Journal, 45, ss.101 - 103, 2023. 10.14744/etd.2022.21043 |
| ISNAD | MUTLU, EMEL vd. "Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report". Erciyes Medical Journal 45/1 (2023), 101-103. https://doi.org/10.14744/etd.2022.21043 |
